GATC Health’s President, Dr. Rahul Gupta, Featured on Inside Precision Medicine’s new “Beyond the Breakthroughs” Series

“Can Biotech Fix U.S. Healthcare Faster than Policy?”

Hosted by Jonathan D. Grinstein, PhD

GATC Health is pleased to announce that Dr. Rahul Gupta, President of GATC Health and former White House “drug czar,” was recently featured in Inside Precision Medicine’s new “Beyond the Breakthroughs” podcast. This series features interviews with “people who are shaping the future of medicine.” In this interview, “Can Biotech Fix U.S. Healthcare Faster than Policy?”, Dr. Gupta discussed how next generation biotechnology, like GATC Health’s pioneering AI-driven platform that mimics human biology, can accelerate medical innovation and address critical U.S. healthcare challenges faster than conventional policy measures.

During the interview, Dr. Gupta reflected on his experiences as a clinician and top policymaker, emphasizing persistent issues in American healthcare such as unaffordable medication, inequity, and slow innovation. He described how GATC Health harnesses AI and multiomics to create human digital twins, enabling dramatically faster, less expensive, and more accurate drug discovery—even for rare and ultra-rare diseases.

The technology can predict drug candidates’ positive or negative outcomes in humans with over 10x better than traditional methods, helping to de-risk investments and prioritize the most promising assets. “We now have the technology to predict, almost like looking into a crystal ball for that molecule, what’s wrong with it with 90% certainty, and then work with the molecule to fix that wrong,” Dr. Gupta said.

Dr. Gupta addressed the need to make medical innovations broadly accessible, not just “miracles for the few,” and described the importance of democratizing drug discovery so it benefits patients worldwide, regardless of socioeconomic background. He highlighted GATC Health’s partnership with Lloyd’s of London and MCI to enable innovative insurance products that further reduce the risk for clinical trial investment and the company’s Derisq™ AI Report, which provides risk analysis for biopharma and investors, much like a FICO® score for drug candidates. 

Looking ahead, Dr. Gupta is optimistic about AI’s role in transforming healthcare efficiency and personalizing treatment—such as using genetic data to select the most effective medications for individuals in less time and at lower cost. Dr. Gupta stressed the moral and ethical responsibility to ensure that technological advances drive equity, prevention, and long-term system sustainability.

For more information and to read the full interview, please visit Inside Precision Medicine’s “Beyond the Breakthroughs” series.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.